{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T02:14:53Z","timestamp":1789352093061,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Virological Methods"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.jviromet.2007.05.009","type":"journal-article","created":{"date-parts":[[2007,6,16]],"date-time":"2007-06-16T10:11:17Z","timestamp":1181988677000},"page":"47-55","source":"Crossref","is-referenced-by-count":76,"title":["Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling"],"prefix":"10.1016","volume":"145","author":[{"given":"H.","family":"Vermeiren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Van Craenenbroeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Alen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bacheler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Picchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lecocq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jviromet.2007.05.009_bib1","unstructured":"Bacheler, L., van Marck, H., Maguire, T., Van Den Bulcke, T., de B\u00e9thune, M.-P., Lecocq, P., 2002. The VirtualPhenotype\u2122: quantitative prediction of HIV drug susceptibility from viral genotype. In: Sixth International Congress on Drug Therapy in HIV Infection (Abstract PL5.5)."},{"key":"10.1016\/j.jviromet.2007.05.009_bib2","doi-asserted-by":"crossref","first-page":"F83","DOI":"10.1097\/00002030-200006160-00001","article-title":"A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS","volume":"14","author":"Baxter","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.jviromet.2007.05.009_bib3","doi-asserted-by":"crossref","unstructured":"Birkner, M.D., van der Laan, M.J., 2005. Application of a variable importance measure method to HIV-1 sequence data. U.C. Berkeley Division of Biostatistics Working Paper Series. Working Paper 196.","DOI":"10.2202\/1557-4679.1013"},{"key":"10.1016\/j.jviromet.2007.05.009_bib4","unstructured":"Castor, D., Vlahov, D., Berkman, A., Wu, Y., Hammer, S.M., 2004. Genotypic sensitivity score predicts HIV viral suppression among treatment experienced patients with advanced HIV disease receiving modified DOT MedGenMed. 6. In: The XV International AIDS Conference (Abstract WePeB5751)."},{"key":"10.1016\/j.jviromet.2007.05.009_bib5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/01.aids.0000222069.14878.44","article-title":"Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors","volume":"20","author":"Clark","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.jviromet.2007.05.009_bib6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/00002030-200203080-00009","article-title":"A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy","volume":"16","author":"Cohen","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.jviromet.2007.05.009_bib7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/00001432-200312000-00010","article-title":"Impact of different HIV resistance interpretation by distinct systems on clinical utility of resistance testing","volume":"16","author":"De Luca","year":"2003","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.jviromet.2007.05.009_bib8","first-page":"28","article-title":"Essential benefits of nucleoside analogue regimens in failing therapy","volume":"9","author":"Geretti","year":"2004","journal-title":"J. HIV Ther."},{"key":"10.1016\/j.jviromet.2007.05.009_bib9","first-page":"S143","article-title":"Infrequent occurrence of mutations in the C-terminal region of reverse transcriptase modulates susceptibility to RT inhibitors","volume":"11","author":"Gupta","year":"2006","journal-title":"Antiviral Ther."},{"key":"10.1016\/j.jviromet.2007.05.009_bib10","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1371\/journal.pctr.0010018","article-title":"A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: The CREST Study","volume":"1","author":"Hales","year":"2006","journal-title":"PLoS Clin Trials"},{"key":"10.1016\/j.jviromet.2007.05.009_bib11","doi-asserted-by":"crossref","first-page":"F33","DOI":"10.1097\/00002030-200210180-00001","article-title":"The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis","volume":"16","author":"Haubrich","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.jviromet.2007.05.009_bib12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1086\/375597","article-title":"Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel","volume":"37","author":"Hirsch","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jviromet.2007.05.009_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/2529336","article-title":"The analysis and selection of variables in linear regression","volume":"32","author":"Hocking","year":"1976","journal-title":"Biometrics"},{"key":"10.1016\/j.jviromet.2007.05.009_bib14","first-page":"125","article-title":"Update of the drug resistance mutations in HIV-1: Fall 2005","volume":"13","author":"Johnson","year":"2005","journal-title":"Top. HIV Med."},{"key":"10.1016\/j.jviromet.2007.05.009_bib15","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jviromet.2007.05.009_bib16","unstructured":"Melnick, D., Rosenthal, J., Cameron, M., Snyder, M., Griffith-Howard, S., Hertogs, K., Verbiest, W., Graham, N., Pham, S., 2000. Impact of phenotypic antiretroviral drug resistance testing on the response to salvage antiretroviral therapy (ART) in heavily experienced patients. In: Seventh Conference on Retroviruses and Opportunistic Infect. (Abstract 786)."},{"key":"10.1016\/j.jviromet.2007.05.009_bib17","first-page":"S44","article-title":"Susceptibility to saquinavir and atazanavir in highly protease inhibitor (PI) resistant HIV-1 is caused by lopinavir-induced drug resistance mutation L76V","volume":"9","author":"Mueller","year":"2004","journal-title":"Antiviral Ther."},{"key":"10.1016\/j.jviromet.2007.05.009_bib18","unstructured":"Panel on Clinical Practices for Treatment of HIV Infection, U.D.o.H.a.H.S., 2006. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents."},{"key":"10.1016\/j.jviromet.2007.05.009_bib19","unstructured":"Rinehart, A., Lecocq, P., Winters, B., Mc Kenna, P., Pattery, T., Wasikowski, B., Bacheler, L.T., Sista, P. Retrospective Analysis of Trends in Genotypic and Predicted Phenotypic HIV-1 Resistance between 1999 and 2005, in preparation."},{"key":"10.1016\/j.jviromet.2007.05.009_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/jmv.20500","article-title":"Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors","volume":"78","author":"Saracino","year":"2006","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jviromet.2007.05.009_bib21","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1093\/bioinformatics\/bti623","article-title":"ROCR: visualizing classifier performance in R","volume":"21","author":"Sing","year":"2005","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jviromet.2007.05.009_bib22","doi-asserted-by":"crossref","unstructured":"Sinisi, S.E., Petersen, M.L., van der Laan, M.J., 2006. Super learning: an application to prediction of HIV-1 drug susceptibility. U.C. Berkeley Division of Biostatistics Working Paper Series. Working Paper 206.","DOI":"10.2202\/1544-6115.1240"},{"key":"10.1016\/j.jviromet.2007.05.009_bib23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/0003-4819-139-5_Part_1-200309020-00006","article-title":"Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial","volume":"139","author":"Squires","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jviromet.2007.05.009_bib24","doi-asserted-by":"crossref","first-page":"7186","DOI":"10.1128\/JVI.02084-05","article-title":"Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors","volume":"80","author":"Svicher","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.jviromet.2007.05.009_bib25","unstructured":"Van Der Borght, K., Vermeiren, H., Lecocq, P., Pattery, T., Alen, P., Bacheler, L., Picchio, G., 2006. The effects of the 76V mutation on protease-inhibitor (PI) susceptibility are PI- and context-specific. In: 16th International AIDS Conference (Abstract THPE0038)."},{"key":"10.1016\/j.jviromet.2007.05.009_bib26","doi-asserted-by":"crossref","DOI":"10.2202\/1557-4679.1008","article-title":"Statistical inference for variable importance","volume":"2","author":"van der Laan","year":"2006","journal-title":"Int. J. Biostat."},{"key":"10.1016\/j.jviromet.2007.05.009_bib27","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study","volume":"363","author":"van Leth","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jviromet.2007.05.009_bib28","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/135965350400900619","article-title":"Updated European recommendations for the clinical use of HIV drug resistance testing","volume":"9","author":"Vandamme","year":"2004","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jviromet.2007.05.009_bib29","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/135965350400900307","article-title":"Simple linear model provides highly accurate genotypic predictions of HIV-1 drug resistance","volume":"9","author":"Wang","year":"2004","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jviromet.2007.05.009_bib30","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1086\/381266","article-title":"Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial","volume":"38","author":"Wegner","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jviromet.2007.05.009_bib31","doi-asserted-by":"crossref","first-page":"F41","DOI":"10.1097\/00002030-200210180-00002","article-title":"Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates","volume":"16","author":"Whitcomb","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.jviromet.2007.05.009_bib32","unstructured":"Winters, B., Montaner, J., Harrigan, P.R., Gazzard, B., Pozniak, A., Miller, M., Emery, S., van Leth, F., Robinson, P., Baxter, J.D., Perez-Elias, M., Castor, D., Hammer, S., Vermeiren, H., Van Craenenbroeck, E., Rinehart, A., Bacheler, L. Determination of Clinically Relevant Cut-offs for HIV-1 Phenotypic Resistance Estimates through a Combined Analysis of Clinical Trial and Cohort Data, in preparation."}],"container-title":["Journal of Virological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093407001735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166093407001735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T07:37:35Z","timestamp":1683877055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166093407001735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0166093407001735"],"URL":"https:\/\/doi.org\/10.1016\/j.jviromet.2007.05.009","relation":{},"ISSN":["0166-0934"],"issn-type":[{"value":"0166-0934","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}